相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma based on formalin-fixed paraffin-embedded samples
Xiao Li et al.
BMC CANCER (2013)
Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel
Hao Wu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Downregulation of miR-17∼92 Expression Increase Paclitaxel Sensitivity in Human Ovarian Carcinoma SKOV3-TR30 Cells via BIM Instead of PTEN
Ting Shuang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
miR-125b Functions as a Key Mediator for Snail-induced Stem Cell Propagation and Chemoresistance
Zixing Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Let-7c Governs the Acquisition of Chemo- or Radioresistance and Epithelial-to-Mesenchymal Transition Phenotypes in Docetaxel-Resistant Lung Adenocarcinoma
Shi-Yun Cui et al.
MOLECULAR CANCER RESEARCH (2013)
miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis
S. Catuogno et al.
ONCOGENE (2013)
Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET
T. Mitamura et al.
ONCOGENESIS (2013)
Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
Martin Puhr et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
miRNA-34a is associated with docetaxel resistance in human breast cancer cells
L. Kastl et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3
Bing Feng et al.
CANCER (2012)
MiRNA-21 A biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer
Wen Gao et al.
CANCER BIOLOGY & THERAPY (2012)
Reversal of Paclitaxel Resistance in Epithelial Ovarian Carcinoma Cells by a MUC1 Aptamer-let-7i Chimera
Nenghui Liu et al.
CANCER INVESTIGATION (2012)
MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1
Bing Feng et al.
CANCER LETTERS (2012)
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
Libero Santarpia et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1
Benjamin Boyerinas et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer
Fiona Furlong et al.
JOURNAL OF PATHOLOGY (2012)
Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells
Kezhen Lv et al.
PLOS ONE (2012)
MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN
Zhao-Xia Wang et al.
ARCHIVES OF MEDICAL RESEARCH (2011)
miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression
Jian Li et al.
CANCER LETTERS (2011)
Regulation of β-Tubulin Isotypes by Micro-RNA 100 in MCF7 Breast Cancer Cells
Sharon Lobert et al.
CYTOSKELETON (2011)
PLK1 as an oncology target: current status and future potential
Campbell McInnes et al.
DRUG DISCOVERY TODAY (2011)
The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients
Susanna Leskelae et al.
ENDOCRINE-RELATED CANCER (2011)
Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein
Bao Hua Li et al.
EUROPEAN JOURNAL OF CANCER (2011)
MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management
Lingeng Lu et al.
GYNECOLOGIC ONCOLOGY (2011)
MicroRNA EXPRESSION PROFILES OF HEAD AND NECK SQUAMOUS CELL CARCINOMA WITH DOCETAXEL-INDUCED MULTIDRUG RESISTANCE
Yuemeng Dai et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia
Dan-Dan Feng et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2
Ji-guang Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells
Jian Li et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS
Bin Xu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Frequent Gene Products and Molecular Pathways Altered in Prostate Cancer- and Metastasis-Initiating Cells and Their Progenies and Novel Promising Multitargeted Therapies
Murielle Mimeault et al.
MOLECULAR MEDICINE (2011)
miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo
A. Holleman et al.
ONCOGENE (2011)
Serum miRNA-21: Elevated Levels in Patients With Metastatic Hormone-Refractory Prostate Cancer and Potential Predictive Factor for the Efficacy of Docetaxel-Based Chemotherapy
Hai-Liang Zhang et al.
PROSTATE (2011)
MicroRNAs as therapeutic targets in cancer
S. Patrick Nana-Sinkam et al.
TRANSLATIONAL RESEARCH (2011)
Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells
Guo-hai Shi et al.
ACTA PHARMACOLOGICA SINICA (2010)
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1
Zhongxing Liang et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions
Li Xie et al.
BMC CANCER (2010)
MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol
Yu Ren et al.
BMC CANCER (2010)
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment
Kelly K. Haagenson et al.
CANCER AND METASTASIS REVIEWS (2010)
MicroRNA-21 A novel therapeutic target in human cancer
Xuan Pan et al.
CANCER BIOLOGY & THERAPY (2010)
MicroRNA and drug resistance
J. Ma et al.
CANCER GENE THERAPY (2010)
The miR-34 family in cancer and apoptosis
H. Hermeking
CELL DEATH AND DIFFERENTIATION (2010)
The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer?
Simone Brabletz et al.
EMBO REPORTS (2010)
MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells
Zhimin Li et al.
GYNECOLOGIC ONCOLOGY (2010)
MiR-148a Attenuates Paclitaxel Resistance of Hormone-refractory, Drug-resistant Prostate Cancer PC3 Cells by Regulating MSK1 Expression.
Yasunori Fujita et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression
Ming Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1)
Wang Rui et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
miR-21: an oncomir on strike in prostate cancer
Marco Folini et al.
MOLECULAR CANCER (2010)
Human Mutations That Confer Paclitaxel Resistance
Shanghua Yin et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Targeting microRNAs in cancer: rationale, strategies and challenges
Ramiro Garzon et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol
S. Radulescu et al.
ONCOGENE (2010)
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
A. Singh et al.
ONCOGENE (2010)
Inhibition of c-FLIP expression by miR-512-3p contributes to Taxol-induced apoptosis in hepatocellular carcinoma cells
Feng Chen et al.
ONCOLOGY REPORTS (2010)
MiR-34a Attenuates Paclitaxel-Resistance of Hormone-Refractory Prostate Cancer PC3 Cells Through Direct and Indirect Mechanisms
Keitaro Kojima et al.
PROSTATE (2010)
Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection
Robert E. Lanford et al.
SCIENCE (2010)
Programmed Cell Death Protein 4 Down-regulates Y-Box Binding Protein-1 Expression via a Direct Interaction with Twist1 to Suppress Cancer Cell Growth
Masaki Shiota et al.
CANCER RESEARCH (2009)
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy
Todd Boren et al.
GYNECOLOGIC ONCOLOGY (2009)
miR-21: a small multi-faceted RNA
Anna M. Krichevsky et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
Dawn R. Cochrane et al.
MOLECULAR CANCER THERAPEUTICS (2009)
MECHANISMS OF DISEASE Cell Death
Richard S. Hotchkiss et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3
Wing Pui Tsang et al.
APOPTOSIS (2008)
Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells
Hua Zhu et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres
Qing Ji et al.
BMC CANCER (2008)
Role of microRNAs in drug-resistant ovarian cancer cells
Antonio Sorrentino et al.
GYNECOLOGIC ONCOLOGY (2008)
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
Olga Kovalchuk et al.
MOLECULAR CANCER THERAPEUTICS (2008)
An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer
Kelly H. Salter et al.
PLOS ONE (2008)
Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases
Fatih M. Uckun
CELL CYCLE (2007)
Class III β-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia
K. M. Lee et al.
HISTOPATHOLOGY (2007)
Adenomatous polyposis coli (APC):: a multi-functional tumor suppressor gene
Koji Aoki et al.
JOURNAL OF CELL SCIENCE (2007)
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs
B. Spaenkuch et al.
ONCOGENE (2007)
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
L. Pusztai
ANNALS OF ONCOLOGY (2007)
Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts
P Paulus et al.
CANCER RESEARCH (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Complex networks orchestrate epithelial-mesenchymal transitions
JP Thiery et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
P Sève et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Microtubule associated protein (MAP)-Tau - A novel mediator of paclitaxel sensitivity in vitro and in vivo
P Wagner et al.
CELL CYCLE (2005)
Partial downregulation of MAD1 causes spindle checkpoint inactivation and aneuploidy, but does not confer resistance towards taxol
A Kienitz et al.
ONCOGENE (2005)
Docetaxel for treatment of solid tumours: a systematic review of clinical data
A Montero et al.
LANCET ONCOLOGY (2005)
βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability
K Kamath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Do β-tubulin mutations have a role in resistance to chemotherapy?
HK Berrieman et al.
LANCET ONCOLOGY (2004)
Mechanisms of Taxol resistance related to microtubules
GA Orr et al.
ONCOGENE (2003)
Securin and B-cyclin/CDK are the only essential targets of the APC
BR Thornton et al.
NATURE CELL BIOLOGY (2003)
Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation
R. Z. Yusuf et al.
CURRENT CANCER DRUG TARGETS (2003)
Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
M. Abal et al.
CURRENT CANCER DRUG TARGETS (2003)
E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints
B Ren et al.
GENES & DEVELOPMENT (2002)
Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells
C Lanzi et al.
PROSTATE (2001)
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53
SS Bacus et al.
ONCOGENE (2001)
分享论文
